Pomin Vitor H
Program of Glycobiology, Institute of Medical Biochemistry Leopoldo de Meis, University Hospital Clementino Fraga Filho, Federal University of Rio de Janeiro, Rio de Janeiro, RJ 21941-913, Brazil.
Pharmaceuticals (Basel). 2015 Dec 10;8(4):848-64. doi: 10.3390/ph8040848.
Sulfated fucans (SFs) and sulfated galactans (SGs) are currently the marine non-glycosaminoglycan (GAG) sulfated glycans most studied in glycomics. These compounds exhibit therapeutic effects in several pathophysiological systems such as blood coagulation, thrombosis, neovascularization, cancer, inflammation, and microbial infections. As analogs of the largely employed GAGs and due to some limitations of the GAG-based therapies, SFs and SGs comprise new carbohydrate-based therapeutics available for clinical studies. Here, the principal structural features and the major mechanisms of action of the SFs and SGs in the above-mentioned pathophysiological systems are presented. Discussion is also given on the current challenges and the future perspectives in drug development of these marine glycans.
硫酸化岩藻聚糖（SFs）和硫酸化半乳聚糖（SGs）是目前糖组学中研究最多的海洋非糖胺聚糖（GAG）硫酸化聚糖。这些化合物在多种病理生理系统中展现出治疗作用，如血液凝固、血栓形成、新血管生成、癌症、炎症和微生物感染。作为大量应用的GAG的类似物，并且由于基于GAG的疗法存在一些局限性，SFs和SGs构成了可用于临床研究的新型碳水化合物类治疗药物。在此，介绍了SFs和SGs在上述病理生理系统中的主要结构特征和主要作用机制。还讨论了这些海洋聚糖在药物开发方面当前面临的挑战和未来前景。
